Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
You may also be interested in...
Higher DHA Fatty Acids Linked To Almost 50% Reduction In Alzheimer’s Risk – Framingham Study
Researchers with 1,490 patients in multigenerational cardiovascular study found subjects with higher levels of DHA omega-3s a lower chance of developing Alzheimer’s.
Lexeo’s Approach To Gene Therapy For Common Conditions
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
Precision And Prevention Key To Future Of Alzheimer’s Treatment
While a so-called disease modifying treatment has entered the market for the first time, in the form of Biogen’s Aduhelm, Alzheimer’s disease is unlikely to be cured by one drug alone. In Vivo explores the array of approaches to AD drug development, drawing on interviews with industry leaders and pipeline data.